coronaviru
diseas
pandem
pose
enorm
challeng
healthcar
system
affect
commun
older
patient
preexist
medic
condit
identifi
popul
risk
sever
diseas
cours
remain
unclear
point
extent
chronic
liver
diseas
consid
risk
factor
due
shortag
appropri
studi
howev
patient
advanc
liver
diseas
liver
transplant
repres
vulner
patient
cohort
increas
risk
infect
andor
sever
cours
addit
current
pandem
requir
unusu
alloc
healthcar
resourc
may
neg
impact
care
patient
chronic
liver
diseas
continu
requir
medic
attent
thu
challeng
hepatologist
face
promot
telemedicin
outpati
set
prioritis
outpati
contact
avoid
nosocomi
dissemin
viru
patient
healthcar
provid
time
maintain
standard
care
patient
requir
immedi
medic
attent
coronaviru
diseas
caus
recent
identifi
coronaviru
sever
acut
respiratori
syndrom
coronaviru
symptom
associ
mostli
fever
tired
dri
cough
patient
also
develop
symptom
includ
short
breath
ach
nasal
congest
sore
throat
anosmia
ageusia
nausea
vomit
diarrhoea
occur
less
frequent
symptom
remain
mild
throughout
cours
infect
major
patient
older
patient
identifi
higher
risk
fatal
diseas
cours
hypertens
diabet
coronari
heart
diseas
frequent
comorbid
cohort
liver
preexist
liver
diseas
specif
list
publish
cohort
studi
elev
alanin
aminotransferas
alt
level
reduc
platelet
count
reduc
albumin
level
time
admiss
associ
higher
mortal
although
alter
independ
risk
factor
remain
unclear
time
whether
laboratori
test
alter
sign
preexist
liver
diseas
patient
sever
cours
infect
whether
rather
reflect
liver
damag
caus
viru
whether
mirror
sever
inflammatori
respons
hypoalbuminemia
dissemin
intravascular
coagul
thrombocytopenia
possibl
patient
advanc
chronic
liver
diseas
increas
risk
infect
due
cirrhosisassoci
immun
dysfunct
could
true
patient
liver
transplant
possibl
autoimmun
liver
diseas
receiv
immunosuppress
therapi
howev
current
limit
data
avail
link
underli
liver
diseas
cours
infect
mani
open
question
box
chronic
hepat
b
viru
infect
exampl
preval
china
europ
appear
affect
outcom
addit
although
proof
assumpt
immunosuppress
may
even
provid
protect
immunopatholog
appear
contribut
lung
damag
case
sever
manifest
diseas
may
associ
macrophag
activ
syndrom
context
hyperinflammatori
syndrom
characteris
cytokin
storm
multiorgan
failur
hand
system
viral
infect
often
associ
transient
elev
transaminas
may
reflect
gener
immun
activ
inflamm
caus
circul
cytokin
without
compromis
liver
function
phenomenon
call
bystand
hepat
may
also
case
patient
liver
failur
specif
report
even
sever
fatal
cours
diseas
howev
sign
liver
dysfunct
may
occur
critic
ill
patient
review
whether
patient
cirrhosi
increas
risk
decompens
develop
acuteonchron
liver
failur
aclf
shown
influenza
infect
remain
determin
may
also
directli
infect
liver
cell
receptor
viru
angiotensinconvert
enzym
shown
express
cholangiocyt
may
explain
case
viral
shed
faec
far
observ
asian
cohort
transfer
european
popul
remain
determin
appear
unlik
infect
caus
liver
damag
amount
substanti
contribut
overal
diseas
burden
asid
direct
implic
liver
diseas
cours
vice
versa
sever
addit
aspect
requir
attent
current
pandem
amount
avail
informationinclud
misinform
rumoursresult
uncertainti
concern
among
patient
also
healthcar
provid
threat
pose
underestim
remain
import
maintain
care
patient
chronic
liver
diseas
identifi
potenti
way
prioritis
care
patient
time
limit
healthcar
resourc
recommend
provid
address
specif
characterist
patient
liver
diseas
meant
provid
addit
guidanc
care
patient
gener
recommend
guidelin
regard
prevent
diagnosi
treatment
local
author
adher
manag
surveil
patient
advanc
liver
diseas
receiv
immunosuppress
treatment
often
perform
larger
unit
centr
institut
howev
current
also
hotspot
thu
potenti
put
outpati
chronic
liver
diseas
risk
nosocomi
infect
addit
hospit
staff
face
challeng
long
work
hour
even
reduc
staf
quarantin
therefor
sever
factor
consid
hepatologist
provid
care
vulner
patient
clearli
prioritis
criteria
need
defin
outpati
contact
gener
specif
recommend
provid
fig
comprehens
cover
patient
cohort
back
dataset
moreov
precis
manag
patient
strongli
depend
local
burden
case
patient
advanc
chronic
liver
diseas
recommend
admiss
inpati
care
depend
presenc
certain
risk
factor
discuss
detail
separ
section
physic
distanc
suggest
andor
offici
implement
multipl
countri
across
globe
prevent
dissemin
measur
aim
prevent
rapid
increas
infect
gener
popul
overal
goal
minimis
number
patient
sever
cours
one
time
enabl
healthcar
provid
maintain
medicalintens
care
patient
time
vulner
patient
cohort
protect
individu
potenti
exposur
infect
thu
patient
benefit
maintain
patient
care
weigh
risk
infect
consider
requir
adapt
standard
oper
procedur
outpati
care
includ
remodel
wait
area
allow
suffici
distanc
patient
reduct
wait
time
encourag
patient
wait
outsid
wherev
possibl
eventu
contact
phone
addit
exposur
medic
staff
minimis
wherev
possibl
facetofac
contact
basi
physicianpati
relationship
allow
physician
quickli
assess
overal
condit
patient
howev
due
amount
individu
contact
physician
risk
infect
subsequ
also
dissemin
viru
thu
seem
appropri
also
limit
amount
facetofac
contact
patient
risk
sever
cours
infect
technic
solut
avail
enabl
remot
physicianpati
interact
benefit
alreadi
discuss
context
pandem
health
author
urg
equip
hospit
system
attend
patient
stay
quarantin
home
also
care
patient
need
protect
potenti
harm
infect
guid
pandem
explain
futur
treatmentmanag
strategiesplan
provid
advic
concern
gener
prevent
measur
current
pandem
clearli
underlin
import
make
technic
solut
avail
health
care
provid
order
better
prepar
situat
like
futur
visit
specialis
centr
postpon
use
telemedicin
visit
phone
wherev
possibl
routin
laboratori
test
perform
local
eg
primari
care
physician
frequenc
need
care
individu
riskbenefit
consider
chronic
viral
hepat
appear
increas
risk
sever
cours
use
telemedicineloc
laboratori
test
followup
visit
patient
antivir
therapi
send
followupprescript
mail
patient
nonalcohol
fatti
liver
diseas
nafld
steatohepat
nash
may
suffer
metabol
comorbid
diabet
hypertens
obes
put
increas
risk
sever
cours
patient
autoimmun
liver
diseas
current
advis
reduc
immunosuppress
therapi
reduct
consid
special
circumst
eg
medicationinduc
lymphopenia
bacteri
fungal
superinfect
case
sever
consult
specialist
emphasi
import
vaccin
streptococcu
pneumonia
influenza
patient
compens
cirrhosi
consid
delay
hepatocellular
carcinoma
hcc
surveil
screen
varic
noninvas
risk
assess
presenc
varic
appli
stratif
thrombocyt
count
baveno
vi
see
also
section
liverrel
diagnost
procedur
gener
consider
care
maintain
accord
guidelin
consid
minim
exposur
medic
staff
use
telemedicinevisit
phone
wherev
possiblerequir
avoid
admiss
list
transplant
restrict
patient
poor
shortterm
prognosi
includ
acuteacuteonchron
liver
failur
alfaclf
high
model
endstag
liver
diseas
meld
score
includ
except
meld
hcc
upper
limit
milan
criteria
transplant
activ
organ
donat
like
reduc
mani
countri
area
reduc
inhospit
liver
transplant
evalu
program
strictli
necessari
recommend
shorten
inhospit
stay
also
reduc
number
consult
departmentsclin
ie
ophthalmolog
dermatolog
dental
neurolog
consult
done
local
outpati
set
emphasi
import
vaccin
streptococcu
pneumonia
influenza
patient
decompens
liver
diseas
includ
hepatocelullar
carcinoma
patient
chronic
liver
diseas
adher
common
rule
physic
distanc
care
maintain
accord
guidelin
minim
exposur
medic
staff
use
telemedicinevisit
phone
wherev
possiblerequir
avoid
admiss
list
transplant
restrict
patient
poor
shortterm
prognosi
transplant
activitiesorgan
donat
like
reduc
mani
countri
area
reduc
inhospit
liver
transplant
evalu
program
strictli
necessari
recommend
shorten
hospit
stay
emphasi
import
vaccin
streptococcu
pneumonia
influenza
guidelin
prophylaxi
spontan
bacteri
periton
hepat
encephalopathi
close
follow
avoid
admiss
includ
test
patient
acut
decompens
acuteonchron
liver
failur
guidelin
prophylaxi
spontan
bacteri
periton
hepat
encephalopathi
close
follow
prevent
decompens
avoid
admiss
includ
test
patient
acut
decompens
aclf
specif
consider
patient
activ
list
transplant
routin
test
perform
transplant
donor
recipi
acknowledg
neg
test
complet
rule
infect
consent
diagnost
therapeut
procedur
relat
transplant
includ
potenti
risk
nosocomi
livingdonor
transplant
consid
casebycas
basi
care
maintain
accord
guidelin
includ
continu
system
treatment
evalu
liver
transplant
consid
minim
exposur
medic
staff
use
telemedicinevisit
phone
wherev
possiblerequir
avoid
admiss
case
earli
admiss
recommend
see
also
section
inpati
care
maintain
care
accord
guidelin
consid
minim
exposur
medic
staff
use
telemedicinevisit
phone
wherev
possiblerequir
avoid
admiss
emphasi
import
vaccin
streptococcu
pneumonia
influenza
stabl
patient
perform
local
laboratori
test
includ
drug
level
current
advis
reduct
immunosuppress
therapi
reduct
consid
special
circumst
eg
medicationinduc
lymphopenia
bacterialfung
superinfect
case
sever
consult
specialist
liverrel
diagnost
procedur
endoscopi
patient
without
depend
avail
resourc
screen
varic
esophagogastroduodenoscopi
egd
reserv
patient
risk
varic
bleed
patient
histori
varic
bleed
sign
signific
portal
hypertens
ascit
thrombocyt
count
noninvas
risk
assess
presenc
varic
appli
stratif
thrombocyt
count
baveno
vi
endoscop
retrograd
cholangiographi
erc
dilat
stent
replac
patient
liver
transplant
patient
primari
scleros
cholang
perform
care
individu
riskbenefit
consider
includ
risk
nosocomi
infect
depend
local
burden
patient
endoscop
procedur
associ
increas
risk
dissemin
egd
erc
spread
viruscontain
droplet
occur
addit
shed
viru
faec
increas
risk
dissemin
colonoscopi
thu
indic
endoscop
procedur
patient
limit
emerg
gastrointestin
bleed
bacteri
cholang
lifethreaten
condit
patient
without
hcc
surveil
defer
base
avail
resourc
includ
avail
therapeut
option
case
hcc
diagnosi
centr
individu
risk
assess
patient
increas
risk
patient
elev
alphafetoprotein
level
advanc
cirrhosi
chronic
hepat
b
nashdiabet
etc
may
prioritis
resourc
limit
patient
hcc
surveil
defer
recoveri
necess
reduc
travel
limit
visit
specialis
centr
challeng
liver
diseas
patient
local
health
care
provid
alik
order
facilit
decentralis
care
patient
close
collabor
specialis
hepatologist
local
health
care
provid
requir
pertain
sever
factor
commun
immunosuppress
target
level
patient
liver
transplant
manag
patient
sever
alt
elev
unknown
aetiolog
other
thu
recommend
specialis
centr
provid
easili
access
contact
inform
local
health
care
provid
facilit
fast
uncompl
collabor
benefit
patient
liver
diseas
alt
elev
frequent
clinic
appar
liver
injuri
jaundic
seem
rare
patient
decompens
cirrhosi
treat
mani
patient
chronic
liver
diseas
continu
requir
inpati
care
crisi
decompens
cholang
reject
complic
gener
measur
prevent
exposur
infect
utmost
import
patient
depend
local
infrastructur
implement
ward
hospit
warrant
howev
base
local
sharp
separ
clean
dirti
wardshospit
may
sustain
although
recent
evid
provid
somewhat
reassur
data
regard
absenc
environment
contamin
rna
inanim
surfac
outsid
patient
room
wherev
possibl
patient
chronic
liver
diseas
requir
inpati
care
caus
admit
ward
hospit
institut
may
abl
provid
specialis
hepatologycar
similar
recommend
outpati
care
recommend
specialis
centr
provid
easili
access
contact
inform
facilit
immedi
hepatolog
consult
howev
due
contagi
viru
patient
underli
liver
diseas
becom
infect
subsequ
requir
inpati
care
regard
nosocomialinfect
recent
observ
spain
compar
patient
characterist
patient
communityacquir
influenza
nosocomialacquir
influenza
could
detect
signific
differ
cohort
regard
underli
chronic
liver
diseas
whether
observ
also
hold
context
pandem
remain
proven
evid
emerg
recommend
patient
chronic
liver
diseas
admit
inpati
care
addit
risk
factor
sever
cours
like
hypertens
diabet
obes
cirrhosi
hcc
posttranspl
statu
although
current
drug
approv
sever
repurpos
drug
test
recent
week
mani
still
investig
see
tabl
remdesivir
act
adenosineanalogu
induc
rna
chain
termin
initi
develop
antivir
agent
ebola
recent
shown
inhibit
clinic
isol
vitro
reduc
diseas
sever
relat
merscovinfect
nonhuman
primat
model
vivo
addit
sever
report
suggest
clinic
efficaci
patient
suffer
clinic
trial
ongo
evalu
efficaci
affect
patient
although
ritonavirboost
lopinavir
show
antivir
effect
vitro
recent
publish
clinic
trial
patient
sever
show
effect
vivo
compar
treatment
drug
current
evalu
includ
chloroquin
phosphat
hydroxychloroquin
chloroquin
shown
antivir
efficaci
vitro
interfer
mediat
endocytosi
wide
use
treatment
patient
sever
monotherapi
also
combin
azithromycin
administr
compound
infect
patient
remain
individu
decis
efficaci
optim
time
remain
clarifi
howev
regard
patient
chronic
liver
diseas
possibl
advers
event
kept
mind
particularli
import
respect
druginteract
patient
certain
immunosuppress
therapi
drug
level
cyclosporin
tacrolimu
sirolimu
everolimu
close
monitor
addit
patient
impair
liver
function
high
risk
drug
toxic
ie
patient
childpugh
bc
cirrhosi
tabl
summaris
consider
regard
potenti
toxic
patient
also
import
stress
drug
current
investig
approv
howev
given
earli
initi
antivir
therapi
known
blunt
cours
influenza
reason
assum
earli
treatment
initi
might
also
benefici
prevent
sever
pneumonia
thu
patient
liver
diseas
risk
factor
sever
cours
diseas
recommend
inclus
earli
antivir
treatment
programm
clinic
trial
might
activ
differ
centr
consid
earli
admiss
accord
presenc
addit
risk
factor
inclus
clinic
trial
experiment
antivir
therapi
follow
local
guidelin
see
tabl
guidanc
regard
cld
prevent
acetaminophen
overdos
gday
consid
safe
patient
cirrhosi
without
activ
alcohol
consumpt
list
intend
give
treatment
recommend
evid
use
drug
low
multipl
rct
abovement
drug
drug
ongo
patient
infect
angiotensinconvert
enzym
alt
alanin
aminotransferas
ast
aspart
aminotransferas
coronaviru
diseas
nuc
nucleosid
analogu
pi
proteas
inhibitor
rdrp
rnadepend
rna
polymeras
sever
acut
respiratori
syndrom
coronaviru
drug
list
includ
frequent
discuss
agent
drug
may
lack
clinic
efficaci
consid
base
vitro
observ
mode
action
administ
nonsteroid
antiinflammatori
drug
patient
cirrhosi
portal
hypertens
see
also
section
liverrel
diagnost
procedur
recommend
endoscopi
hcc
surveil
liver
biopsi
specif
consider
patient
chronic
liver
diseas
patient
decompens
cirrhosi
treatment
cirrhosisassoci
complic
portal
hypertens
ascit
hepat
encephalopathi
spontan
bacteri
periton
etc
continu
patient
hcc
locoregion
therapi
postpon
whenev
possibl
immunecheckpoint
inhibitor
therapi
temporarili
withdrawn
decis
whether
continu
reduc
dose
kinas
inhibitor
nonsever
taken
casebycas
basi
patient
liver
transplant
dose
adjust
calceurinandor
mtorinhibitor
might
requir
depend
antivir
therapi
initi
tabl
angiotensinconvert
enzym
acei
angiotensinconvert
enzym
inhibitor
aclf
acuteonchron
liver
failur
alt
alanin
aminotransferas
ast
aspart
aminotransferas
coronaviru
diseas
egd
esophagogastroduodenoscopi
erc
endoscop
retrograd
cholangiographi
hcc
hepatocellular
carcinoma
meld
model
endstag
liver
diseas
nafld
nonalcohol
fatti
liver
diseas
nash
nonalcohol
steatohepat
nuc
nucleosid
analogu
pi
proteas
inhibitor
rdrp
rnadepend
rna
polymeras
sever
acut
respiratori
syndrom
coronaviru
uln
upper
limit
normal
dr
berg
report
grant
person
fee
nonfinanci
support
gilead
dr
boettler
report
consult
fee
gilead
dr
cornberg
report
person
fee
gilead
author
report
conflict
interest
pleas
refer
accompani
icmj
disclosur
form
detail
